{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T01:28:03Z","timestamp":1775784483153,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["redjournal.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.ijrobp.2016.08.031","type":"journal-article","created":{"date-parts":[[2016,9,9]],"date-time":"2016-09-09T11:25:18Z","timestamp":1473420318000},"page":"1003-1010","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Acute Toxicity and Tumor Response in Locally Advanced Rectal Cancer After Preoperative Chemoradiation Therapy With Shortening of the Overall Treatment Time Using Intensity-Modulated Radiation Therapy With Simultaneous Integrated Boost: A Phase 2 Trial"],"prefix":"10.1016","volume":"96","author":[{"given":"Jasna","family":"But-Hadzic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franc","family":"Anderluh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Brecelj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Edhemovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajra","family":"Secerov-Ermenc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rihard","family":"Hudej","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Jeromen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miran","family":"Kozelj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bojan","family":"Krebs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irena","family":"Oblak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirko","family":"Omejc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrej","family":"Vogrin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vaneja","family":"Velenik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2016.08.031_bib1","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1200\/JCO.2013.53.7753","article-title":"Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: Surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04","volume":"32","author":"O'Connell","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2016.08.031_bib2","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.1200\/JCO.2012.42.8771","article-title":"Clinical outcome of the ACCORD 12\/0405 PRODIGE 2 randomized trial in rectal cancer","volume":"30","author":"G\u00e9rard","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2016.08.031_bib3","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S1470-2045(12)70187-0","article-title":"Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: Initial results of the German CAO\/ARO\/AIO-04 randomised phase 3 trial","volume":"13","author":"R\u00f6del","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2016.08.031_bib4","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1200\/JCO.2011.39.6036","article-title":"Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C)","volume":"30","author":"Dewdney","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2016.08.031_bib5","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/annonc\/mds519","article-title":"Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): A randomized, multicenter, phase II trial SAKK 41\/07","volume":"24","author":"Helbling","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2016.08.031_bib6","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1748-717X-6-105","article-title":"Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: Results of an open-label phase II study","volume":"6","author":"Velenik","year":"2011","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2016.08.031_bib7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1748-717X-5-17","article-title":"Intensity-modulated radiation therapy (IMRT) vs. 3D conformal radiotherapy (3DCRT) in locally advanced rectal cancer (LARC): Dosimetric comparison and clinical implications","volume":"5","author":"Arbea","year":"2010","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2016.08.031_bib8","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.ijrobp.2005.12.056","article-title":"Intensity-modulated radiotherapy in patients with locally advanced rectal cancer reduces volume of bowel treated to high dose levels","volume":"65","author":"Guerrero Urbano","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2016.08.031_bib9","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.ijrobp.2008.10.017","article-title":"Preoperative helical tomotherapy and megavoltage computed tomography for rectal cancer: Impact on the irradiated volume of small bowel","volume":"74","author":"Engels","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2016.08.031_bib10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1748-717X-6-63","article-title":"Intensity modulated radiation therapy (IMRT): Differences in target volumes and improvement in clinically relevant doses to small bowel in rectal carcinoma","volume":"6","author":"Mok","year":"2011","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2016.08.031_bib11","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/j.ijrobp.2011.01.051","article-title":"Reduced acute bowel toxicity in patients treated with intensity-modulated radiotherapy for rectal cancer","volume":"82","author":"Samuelian","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2016.08.031_bib12","doi-asserted-by":"crossref","first-page":"e0124601","DOI":"10.1371\/journal.pone.0124601","article-title":"Postoperative capecitabine with concurrent intensity-modulated radiotherapy or three-dimensional conformal radiotherapy for patients with stage II and III rectal cancer","volume":"10","author":"Lu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ijrobp.2016.08.031_bib13","first-page":"137","article-title":"Acute gastrointestinal toxicity and tumor response with preoperative intensity modulated radiation therapy for rectal cancer","volume":"6","author":"Parekh","year":"2013","journal-title":"Gastrointest Cancer Res"},{"key":"10.1016\/j.ijrobp.2016.08.031_bib14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.radonc.2013.10.026","article-title":"Preoperative intensity-modulated and image-guided radiotherapy with a simultaneous integrated boost in locally advanced rectal cancer: Report on late toxicity and outcome","volume":"110","author":"Engels","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2016.08.031_bib15","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00066-014-0650-0","article-title":"Complete pathological responses in locally advanced rectal cancer after preoperative IMRT and integrated-boost chemoradiation","volume":"190","author":"Hernando-Requejo","year":"2014","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.ijrobp.2016.08.031_bib16","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.radonc.2011.07.030","article-title":"Preoperative concomitant boost intensity-modulated radiotherapy with oral capecitabine in locally advanced mid-low rectal cancer: A phase II trial","volume":"102","author":"Li","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2016.08.031_bib17","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1748-717X-9-70","article-title":"Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II\/III rectal adenocarcinoma: Results of a phase II study","volume":"9","author":"Zhu","year":"2014","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2016.08.031_bib18","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13014-015-0360-5","article-title":"CAPIRI-IMRT: A phase II study of concurrent capecitabine and irinotecan with intensity-modulated radiation therapy for the treatment of recurrent rectal cancer","volume":"10","author":"Cai","year":"2015","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2016.08.031_bib19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ijrobp.2015.05.005","article-title":"NRG Oncology Radiation Therapy Oncology Group 0822: A phase 2 study of preoperative chemoradiation therapy using intensity modulated radiation therapy in combination with capecitabine and oxaliplatin for patients with locally advanced rectal cancer","volume":"93","author":"Hong","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2016.08.031_bib20","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1080\/02841860310012301","article-title":"A systematic overview of radiation therapy effects in rectal cancer","volume":"42","author":"Glimelius","year":"2003","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ijrobp.2016.08.031_bib21","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1245\/s10434-011-2209-y","article-title":"Complete pathologic response after combined modality treatment for rectal cancer and long-term survival: A meta-analysis","volume":"19","author":"Zorcolo","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ijrobp.2016.08.031_bib22","first-page":"693","article-title":"Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial","volume":"47","author":"Velenik","year":"2006","journal-title":"Croat Med J"},{"key":"10.1016\/j.ijrobp.2016.08.031_bib23","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1148\/radiol.2272011747","article-title":"Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathologic comparison","volume":"227","author":"Brown","year":"2003","journal-title":"Radiology"},{"key":"10.1016\/j.ijrobp.2016.08.031_bib24","first-page":"1","article-title":"Prescribing, recording and reporting photon beam therapy (ICRU report 50)","volume":"26","year":"1993","journal-title":"ICRU Rep"},{"key":"10.1016\/j.ijrobp.2016.08.031_bib25","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.radonc.2011.11.011","article-title":"Repeat CT assessed CTV variation and PTV margins for short- and long-course pre-operative RT of rectal cancer","volume":"102","author":"van Triest","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2016.08.031_bib26","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2217\/iim.11.22","article-title":"Dose prescription, reporting and recording in intensity-modulated radiation therapy: A digest of the ICRU Report 83","volume":"3","author":"Gregoire","year":"2011","journal-title":"Imaging Med"},{"key":"10.1016\/j.ijrobp.2016.08.031_bib27","volume":"Vol. 86","author":"Joiner","year":"2009"},{"key":"10.1016\/j.ijrobp.2016.08.031_bib28","unstructured":"Cancer Institute N. Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events v4.0 (CTCAE) 2009. Available at: http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf"},{"key":"10.1016\/j.ijrobp.2016.08.031_bib29","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","article-title":"The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM","volume":"17","author":"Edge","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ijrobp.2016.08.031_bib30","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s003840050072","article-title":"Pathological features of rectal cancer after preoperative radiochemotherapy","volume":"12","author":"Dworak","year":"1997","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.ijrobp.2016.08.031_bib31","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2307\/2530297","article-title":"One-sample multiple testing procedure for phase II clinical trials","volume":"38","author":"Fleming","year":"1982","journal-title":"Biometrics"},{"key":"10.1016\/j.ijrobp.2016.08.031_bib32","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/sim.721","article-title":"Sample size tables for exact single-stage phase II designs","volume":"20","author":"A'Hern","year":"2001","journal-title":"Stat Med"},{"key":"10.1016\/j.ijrobp.2016.08.031_bib33","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301616331467?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301616331467?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,8]],"date-time":"2018-09-08T13:22:27Z","timestamp":1536412947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301616331467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S0360301616331467"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2016.08.031","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute Toxicity and Tumor Response in Locally Advanced Rectal Cancer After Preoperative Chemoradiation Therapy With Shortening of the Overall Treatment Time Using Intensity-Modulated Radiation Therapy With Simultaneous Integrated Boost: A Phase 2 Trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2016.08.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}